H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $3 price target on BioLineRx (BLRX) after the company reported in-line Q1 results, with the analyst seeing BL-8040 continuing to deliver positive data on multiple clinical fronts. Pantginis sees "multiple catalysts across all the ongoing programs" for BioLineRx in 2019 that could end the continuing suffering of the shares, including top-line results in the second half of the year from the "Phase 2 triple combo pancreatic cancer trial of BL-8040, Keytruda and chemotherapy under the company's collaboration with Merck (MRK)."
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
Reports Q1 revenue $15.8B, consensus $15.2B. "Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients," said Robert Davis, chairman and chief executive officer, Merck. "We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them."